ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,459.10
1.11%
US Tech 100
18,514.00
1.00%
Dow Jones
40,589.34
1.64%
Brent Oil
79.745
0.00%
Bitcoin
67,897.08
-0.02%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Guardant Health Inc (GH) Quote

Guardant Health Inc

Guardant Health Inc (GH)

Gamehost Inc
33.00
1.07
(3.35%)
Closed July 27 4:00PM
Delayed by 15 minutes
33.00
-0.02
(-0.06%)
After Hours: 7:11PM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
33.00
Bid
20.50
Ask
77.88
Volume
1,231,875
31.80 Day's Range 33.53
15.81 52 Week Range 41.06
Market Cap
4.038B
Previous Close
31.93
Open
32.73
Last Trade
50
@
33
Last Trade Time
Financial Volume
$ 40,034,897
VWAP
32.4992
Average Volume (3m)
2,044,045
Shares Outstanding
122,369,214
Dividend Yield
-
PE Ratio
-8.43
Earnings Per Share (EPS)
-3.92
Revenue
563.95M
Net Profit
-479.45M

About Guardant Health Inc

Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selectio... Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%. Show more

Sector
Medical Laboratories
Industry
Medical Laboratories
Website
www.guardanthealth.com
Headquarters
Dover, Delaware, USA
Founded
1970
Guardant Health Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker GH. The last closing price for Guardant Health was $31.93. Over the last year, Guardant Health shares have traded in a share price range of $ 15.81 to $ 41.06.

Guardant Health currently has 122,369,214 shares outstanding. The market capitalization of Guardant Health is $3.91 billion. Guardant Health has a price to earnings ratio (PE ratio) of -8.43.

Guardant Health (GH) Options Flow Summary

GH Options Flow

Overall Flow

Bullish

Net Premium

96k

Calls / Puts

100.00%

Buys / Sells

200.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

GH Latest News

More News

Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7...

July 24 2024
Business Wire

Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance

Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid...

July 23 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

July 19 2024
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

July 19 2024
Edgar (US Regulatory)

Form 8-K - Current report

July 18 2024
Edgar (US Regulatory)

Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors

Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Dr. Manuel Hidalgo Medina to its board of directors, effective immediately. Dr. Hidalgo...

July 18 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

July 16 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

July 08 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 17 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 17 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.815.803142032731.1933.5330.5681078831.82354585CS
43103034.07526.37130063730.21130194CS
1213.8972.684458398719.1134.07518.01204404527.16276346CS
2610.0343.665650848922.9734.07515.81197253523.08233981CS
52-5.79-14.926527455538.7941.0615.81179641725.66503126CS
156-85.3-72.1048182587118.3133.8215.81153520441.24078029CS
260-61.39-65.038669350694.39181.0715.81133685459.94630271CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WINTWindtree Therapeutics Inc
$ 8.24
(150.46%)
48.57M
BFIBurgerFi International Inc
$ 0.4206
(97.37%)
313.59M
NBSTWNewbury Street Acquisition Corporation
$ 0.1349
(92.71%)
122.1k
YIBOPlanet Image International Ltd
$ 2.915
(53.43%)
260.07k
CREVCarbon Revolution Public Ltd
$ 9.00
(45.87%)
8.06M
NMHINatures Miracle Holding Inc
$ 0.2035
(-48.06%)
7.69M
TANHTantech Holdings Ltd
$ 0.2585
(-47.23%)
6.75M
DXCMDexCom Inc
$ 64.00
(-40.66%)
53.92M
PSIGPS International Group Ltd
$ 1.42
(-31.40%)
716.26k
POAIPredictive Oncology Inc
$ 1.36
(-27.27%)
6.02M
SLNASelina Hospitality PLC
$ 0.0305
(-18.88%)
408.61M
BFIBurgerFi International Inc
$ 0.4206
(97.37%)
313.59M
NVDANVIDIA Corporation
$ 113.06
(0.69%)
293.33M
SQQQProShares UltraPro Short QQQ
$ 9.10
(-2.88%)
176.49M
SGMOSangamo Therapeutics Inc
$ 0.8612
(28.15%)
123.71M

GH Discussion

View Posts
Monksdream Monksdream 2 months ago
The American biotechnology company Guardant Health, which produces liquid biopsy tests to detect cancer from mutations and other modifications in blood samples,[1] was co-founded by Helmy Eltoukhy and AmirAli Talasaz during 2012–2013.[2][3] According to John Dorfman of the Pittsburgh Tribune-Review, Talasaz and Eltoukhy discovered a technique which "involves detecting and monitoring tumor fragments circulating in the patient's bloodstream", as an alternative to traditional tissue biopsies.[4] The duo met at Stanford University in 2002 and worked together at Illumina, until Talasaz left in 2012.[5]
👍️0
SubPenny0001 SubPenny0001 2 months ago
I would add GH with EXAS both would score on the final outcome. FDA is expected to decide whether to approve Shield later this year.
👍️0
jedijazz jedijazz 2 months ago
For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook. $GH
👍️ 1 💪 1 💯 1
jedijazz jedijazz 2 months ago
$GH -Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer.
👍️ 1 💪 1
jedijazz jedijazz 2 months ago
Guardant Health unveiled initial results from the ECLIPSE study validating the performance of the Shield test at the 2023 DDW meeting. The data served as the basis for Guardant Health’s submission of a premarket approval (PMA) application to the FDA, and the full study results have since been published in the March 2024 issue of The New England Journal of Medicine. An FDA Advisory Panel is scheduled to review the PMA application on May 23.

The full abstracts for Guardant Health and a list of all abstracts being presented at the meeting will be available at the DDW website.

For information and updates from the meeting, follow Guardant Health on LinkedIn, X (Twitter) and Facebook. $GH
👍️ 1 💪 1 😍 1
jedijazz jedijazz 2 months ago
$GH Guardant Health Inc NASDAQ -Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
May 16 2024 - 8:05AM


Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from two real-world studies at the 2024 Digestive Disease Week (DDW) meeting in Washington, DC, highlighting the value of the company’s Shield™ test in colorectal cancer (CRC) screening.

“One in three eligible American adults have not been screened for CRC, in part because the currently available methods are unpleasant or inconvenient,” said AmirAli Talasaz, co-CEO of Guardant Health. “The data we will share at DDW underscores the important role that our Shield blood test can have in both improving screening rates and in detecting more colorectal cancer at an early stage, when it is most treatable. We look forward to sharing this important data at DDW.”
👍️ 1 💯 1
DewDiligence DewDiligence 2 years ago
GH—(-34%/AH)—reports_results_of “Shield” ctDNA—(liquid biopsy)—diagnostic_for colorectal cancer:

https://finance.yahoo.com/news/guardant-health-announces-positive-results-211600504.html

https://finance.yahoo.com/news/1-guardant-dna-blood-test-220041937.html

GH’s data aren’t bad, but they aren’t as good as those for EXAS’s Cologuard, which is based on a stool sample rather than a blood sample.

EXAS is +24%/AH, adding about $2B(!) to its market cap.

In #msg-168735158 (from May 2022), I said: Although GH says Shield is as good as EXAS’ Cologuard and MYNZ’s ColoAlert, I find it hard to believe that a blood test can be as sensitive for CRC (and precancerous lesions) as a stool-based test.I stand by that.
👍️0
jerseyboy jerseyboy 3 years ago
I'm still feeling very good about owning this stock. There is no way I'll sell this before the next five years.
👍️0
jerseyboy jerseyboy 4 years ago
I like the nice, gradual, consistent rise in the share price. I think there is no way to lose money here, and I think the gains will be very substantial over the next two to three years.
👍️0
jerseyboy jerseyboy 4 years ago
So am I. This is THE company I have chosen in which to put my investment dollars that I feel is both a high-growth situation and one in which I am certain not to lose money.
👍️0
PR_12 PR_12 4 years ago
2-3 years I'm thinking this is @ 3-5X current share price
👍️0

Your Recent History

NASDAQ
GH
Guardant Health
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved